Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Free Cash Flow (2022 - 2025)

BioXcel Therapeutics has reported Free Cash Flow over the past 4 years, most recently at -$14.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$14.2 million for Q4 2025, up 4.04% from a year ago — trailing twelve months through Dec 2025 was -$57.6 million (up 20.01% YoY), and the annual figure for FY2025 was -$57.6 million, up 20.01%.
  • Free Cash Flow for Q4 2025 was -$14.2 million at BioXcel Therapeutics, up from -$18.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for BTAI hit a ceiling of -$12.0 million in Q1 2025 and a floor of -$52.4 million in Q1 2023.
  • Median Free Cash Flow over the past 4 years was -$25.0 million (2023), compared with a mean of -$26.3 million.
  • Biggest five-year swings in Free Cash Flow: crashed 60.92% in 2023 and later soared 66.18% in 2024.
  • BioXcel Therapeutics' Free Cash Flow stood at -$38.6 million in 2022, then skyrocketed by 30.48% to -$26.9 million in 2023, then skyrocketed by 44.87% to -$14.8 million in 2024, then rose by 4.04% to -$14.2 million in 2025.
  • The last three reported values for Free Cash Flow were -$14.2 million (Q4 2025), -$18.8 million (Q3 2025), and -$12.6 million (Q2 2025) per Business Quant data.